Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.
J Surg Res. 2011 Nov;171(1):127-35. doi: 10.1016/j.jss.2009.12.016. Epub 2010 Jan 14.
The hepatocyte growth factor receptor c-Met and its ligand hepatocyte growth factor (HGF) have been reported to be involved in cellular motility, growth, and invasion by activating mitogenic signaling pathways. The overexpression of c-Met gene has been found in many malignant cancers, but the roles of c-Met overexpression in SCLC tumors still remain unclear. The aim of the present study was to explore its roles and potential as a therapeutic target for SCLC.
Quantitative real-time RT-PCR and immunohistochemistry assays were performed to detect the expression of c-Met mRNA and protein in SCLC tissue or corresponding non-tumor lung tissue samples. Adenovirus-mediated small interfering RNA (siRNA) was employed to down-regulate the expression of c-Met gene in SCLC cell line (NCI-H446). MTT and colony formation assays were performed to detect in vitro proliferation of NCI-H446 cells. In vitro wound-healing and transwell invasion assays were performed to detect in vitro invasion and metastasis of NCI-H446 cells. Finally, in vivo tumorigenicity and metastasis assays were done to analyze in vivo proliferation and metastasis of NCI-H446 cells in a xenograft model.
We showed that the levels of c-Met mRNA expression were significantly higher in SCLC tissue samples (0.97±0.08) than those in corresponding non-tumor lung tissue samples (0.21±0.02; P<0.05). Additionally, the immunostaining of c-Met protein in SCLC tissues was stronger than that in corresponding non-tumor tissues. Adenovirus-mediated siRNA targeting c-Met could significantly down-regulate c-Met expression, and the specific down-regulation of c-Met expression in SCLC cells could strongly inhibit proliferation of SCLC cells both in vitro and in vivo. Moreover, c-Met down-regulation could also reduce invasion capacity in vitro and metastasis capacity in vivo of SCLC cells.
Taken together, our results indicated that the overexpression of c-Met gene played an important role in the progression and development of SCLC, and adenovirus-mediated siRNA targeting c-Met could potentially be an experimental approach for SCLC gene therapy.
肝细胞生长因子受体 c-Met 及其配体肝细胞生长因子(HGF)已被报道通过激活有丝分裂信号通路参与细胞运动、生长和侵袭。c-Met 基因的过表达已在许多恶性肿瘤中发现,但 c-Met 过表达在 SCLC 肿瘤中的作用仍不清楚。本研究旨在探讨其在 SCLC 中的作用和作为治疗靶点的潜力。
采用定量实时 RT-PCR 和免疫组织化学检测 SCLC 组织或相应非肿瘤肺组织样本中 c-Met mRNA 和蛋白的表达。腺病毒介导的小干扰 RNA(siRNA)用于下调 SCLC 细胞系(NCI-H446)中 c-Met 基因的表达。MTT 和集落形成实验检测 NCI-H446 细胞的体外增殖。体外划痕愈合和 Transwell 侵袭实验检测 NCI-H446 细胞的体外侵袭和转移。最后,进行体内肿瘤发生和转移实验,分析 NCI-H446 细胞在异种移植模型中的体内增殖和转移。
我们发现,SCLC 组织样本中 c-Met mRNA 表达水平(0.97±0.08)明显高于相应的非肿瘤肺组织样本(0.21±0.02;P<0.05)。此外,SCLC 组织中 c-Met 蛋白的免疫染色强度强于相应的非肿瘤组织。腺病毒介导的靶向 c-Met 的 siRNA 可显著下调 c-Met 表达,SCLC 细胞中 c-Met 表达的特异性下调可强烈抑制 SCLC 细胞的体外和体内增殖。此外,c-Met 下调还可降低 SCLC 细胞的体外侵袭能力和体内转移能力。
综上所述,我们的研究结果表明,c-Met 基因的过表达在 SCLC 的进展和发展中起重要作用,腺病毒介导的靶向 c-Met 的 siRNA 可能是 SCLC 基因治疗的一种实验方法。